Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yu-Ling Ma and her team's paper "Ion Channel Targeted Mechanisms of Anti-arrhythmic Chinese Herbal Medicine Xin Su Ning" has been published in Frontiers in Pharmacology.

Yu-Ling

Xin Su Ning (XSN) is a Chinese patented and certified herbal medicine used to treat premature ventricular contractions. A newly published Ma Group study demonstrates XSN’s clinical antiarrhythmic efficacy of 12 years’ use in China without adverse reactions being officially reported.

"The method used and the standard achieved bear high quality and the clinically relevant research in cellular electrophysiology on a traditional herbal medicine aimed to illuminate its clinical antiarrythmic mechanisms." - Dr Yu-Ling Ma.

XSN is only available in China, so the team's discoveries could pave the path for translating XSN to an international standard antiarrhythmic medicine through common effort.

"Due to the multi-component nature of XSN, further studies will reveal the mechanisms of the multi-targeting action of XSN that would help to advance the latest understanding that cardiac arrhythmic diseases are multifactorial and dynamic.

Further studying the action mechanisms of XSN may also help to explain how the multicomponent action helps to reduce/eliminate the adverse reactions that single chemical antiarrhythmic drugs often possess, which has led to concerns regarding the safety of antiarrhythmic drugs used clinically." - Dr Yu-Ling Ma.

The full paper can be viewed here.

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Collaborative MRC grant paves the way to new therapeutic targets for stress and anxiety disorders

Dr Armin Lak, Associate Professor Ed Mann and Professor Zoltán Molnár have been awarded a £733K Project Grant from the Medical Research Council on “Orexinergic projections to neocortex: potential role in arousal, stress and anxiety-related disorders”.